Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSeoul National University Hospital

About this trial

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.

Eligibility criteria

Qualifiers

Aged ≥ 18 years

Sepsis related acute kidney injury requiring continuous renal replacement therapy

Disqualifiers

None

Trial design

Treatments tested in this trial

  • oXiris membrane
  • Polysulfone membrane

Treatment groups

98 Participants
are divided into 1 treatment group